HEALTH PROFESSIONAL · SOURCE READING

Ibrutinib versus rituximab plus ibrutinib

Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 25, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Symptomatic or Progressive Chronic Lymphocytic Leukemia / Treatment Options for Symptomatic or Progressive Chronic Lymphocytic Leukemia (CLL) / BTK inhibitors

Evidence (ibrutinib vs. rituximab plus ibrutinib):

A prospective randomized trial included 208 patients who were previously untreated or had relapsed disease. Patients received rituximab plus ibrutinib or ibrutinib alone.[11]

Source links and citations

A prospective randomized trial included 208 patients who were previously untreated or had relapsed disease. Patients received rituximab plus ibrutinib or ibrutinib alone.[11]

With a median follow-up of 36 months, there was no difference in PFS (86%; HR, 1.04; 95% CI, 0.49−2.20; P = .91).[11][Level of evidence B1]

Source links and citations

Publication references

Read the original reference and check its publication notices.

PubMed 30530801 · Original source

Preserved source evidence · Not medical advice